Trovagene Inc. (NASDAQ:TROV) – Investment analysts at Cantor Fitzgerald upped their FY2016 earnings per share (EPS) estimates for shares of Trovagene in a report issued on Tuesday. Cantor Fitzgerald analyst B. Brokmeier now expects that the brokerage will post earnings of ($1.39) per share for the year, up from their prior estimate of ($1.40). Cantor Fitzgerald currently has a “Buy” rating and a $7.00 target price on the stock.
Trovagene (NASDAQ:TROV) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.03. Trovagene had a negative return on equity of 80.13% and a negative net margin of 8,495.00%.
TROV has been the subject of several other research reports. Zacks Investment Research upgraded shares of Trovagene from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a research note on Wednesday, September 21st. Piper Jaffray Cos. set a $4.00 price target on shares of Trovagene and gave the stock a “hold” rating in a research note on Friday, August 5th. Finally, Maxim Group began coverage on shares of Trovagene in a research note on Wednesday, July 6th. They set a “buy” rating and a $12.00 price target for the company. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Trovagene currently has an average rating of “Hold” and a consensus price target of $6.54.
Trovagene (NASDAQ:TROV) opened at 4.52 on Thursday. Trovagene has a one year low of $2.85 and a one year high of $7.18. The firm’s market capitalization is $136.26 million. The stock’s 50 day moving average is $4.82 and its 200 day moving average is $4.91.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its position in Trovagene by 1.3% in the first quarter. Geode Capital Management LLC now owns 183,442 shares of the company’s stock worth $853,000 after buying an additional 2,363 shares in the last quarter. BlackRock Investment Management LLC raised its position in Trovagene by 5.6% in the second quarter. BlackRock Investment Management LLC now owns 113,232 shares of the company’s stock worth $513,000 after buying an additional 5,964 shares in the last quarter. Rhumbline Advisers raised its position in Trovagene by 39.3% in the second quarter. Rhumbline Advisers now owns 39,171 shares of the company’s stock worth $177,000 after buying an additional 11,044 shares in the last quarter. First Heartland Consultants Inc. acquired a new position in Trovagene during the second quarter worth $103,000. Finally, Vanguard Group Inc. raised its position in Trovagene by 3.2% in the second quarter. Vanguard Group Inc. now owns 979,014 shares of the company’s stock worth $4,435,000 after buying an additional 30,369 shares in the last quarter. Institutional investors and hedge funds own 31.06% of the company’s stock.
Trovagene Company Profile
Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.
Receive News & Ratings for Trovagene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trovagene Inc. and related companies with MarketBeat.com's FREE daily email newsletter.